FDA Approves Wyost (denosumab-bddz), an Interchangeable Biosimilar to Xgeva
FDA Approves Jubbonti (denosumab-bddz), an Interchangeable Biosimilar to Prolia
Tecvayli (teclistamab-cqyv) Biweekly Dosing Approved by the U.S. FDA for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC